References	Age at onset of CIDP (years) /gender	Treatment and response of CIDP	Treatment and response of MN
Witte et al. (7)	43/M	CS, ineffective; PE, improved	CS, ineffective; PE, ineffective; chlorambucil, ineffective
Kohli et al. (8)	18/M	CS, improved	CS, ineffective
Panjwani et al. (9)	55/M	CS, improved	CS, ineffective; IVIg, ineffective
Kanemoto et al. (10)	9/M	CS, improved	CS, improved
Mobbs et al. (11)	81/F	PE+CS+AZT, mild improvement	ND
Wu et al. (12)	53/F	IVIg+CS+PE, no improvement other than tremor	IVIg+CS+PE, ineffective
Wu et al. (12)	62/M	PE, improved; CS, further improvement	PE+CS, improved
Emsley et al. (13)	66/M	Spontaneously improved	ACE inhibitor, improved
Chen et al. (14)	60/M	CS, improved; cyclophosphamide, further improved	CS+cyclophosphamide, improved
Smyth et al. (15)	25/M	PE+MTX, improved	PE+MTX, improved
Wong et al. (16)	36/M	IVIg+CS+PE+cyclosporin or tacrolimus, no improvement	IVIg+CS+PE+cyclosporin or tacrolimus, no improvement
Wong et al. (16)	33/F	CS, improved	CS+cyclophosphamide, improved
Doppler et al. (5)	48/M	IVIg, initial improvement; CS, transiently improved; PE, improved	Complete recovery (treatment efficacy was not well documented)
The present case	78/F	CS, ineffective; IVIg, improved	CS, improved

ACE, angiotensin converting enzyme; AZT, azathioprine; CS, corticosteroids (oral high dose or methylprednisolone pulse therapy); CIDP, chronic inflammatory demyelinating polyneuropathy; CNTN1, contactin-1; CSF, cerebrospinal fluid; F, female; GBS, Guillain-Barré syndrome; IVIg, intravenous immunoglobulin; M, male; MRC, Medical Research Council; MTX, methotrexate; ND, not documented; PE, plasma exchange.